Jan Poth, SciRhom CEO
German antibody company secures €63M for autoimmune disease program
SciRhom has raised €63 million ($70 million) in a Series A to advance its lead monoclonal antibody program through a first-in-human trial set to start …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.